Trial Profile

Phase 1b proof-of-concept clinical trial of OLN324 in patients with either wet (neovascular) age-related macular degeneration (wAMD) or diabetic macular edema (DME) (JADE)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Nov 2025 New trial record
18 Sep 2025 According to an Innovent Biologics media release, company has completed enrollment of over 150 patients with wAMD or DME in the JADE study.
18 Sep 2025 According to an Innovent Biologics media release, the company's partner (Ollin) today announced a clinical update on IBI324, a higher-molar-dose VEGF/Ang2 bispecific antibody in Phase 1b clinical development for patients with wet (neovascular) age-related macular degeneration (wAMD) or diabetic macular edema (DME).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com